Evaluate
Pharma commercial intelligence, news & analysis | Evaluate.
| Date | Investors | Amount | Round |
|---|---|---|---|
N/A | Buyout | ||
| Total Funding | 000k | ||
| GBP | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 |
|---|---|---|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % growth | 18 % | 19 % | 35 % | (1 %) | 16 % | 18 % | 103 % |
| EBITDA | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| Profit | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % profit margin | 15 % | 9 % | 3 % | 13 % | 7 % | 8 % | 24 % |
| EV | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
Source: Company filings or news article
Related Content
Notes (0)
Analytics
Unlock the full power of analytics with a premium account
Track company size and historic growth
Track team composition and strength
Track website visits and app downloads
Tech stack
Tech stackLearn more about the technologies and tools that this company uses.
Investments by Evaluate
Edit
ACQUISITION by Evaluate May 2021
ACQUISITION by Evaluate Sep 2021
ACQUISITION by TriNetX Jan 2022
ACQUISITION by Evaluate Mar 2020
ACQUISITION by Evaluate Jan 2024